Who founded Hepanova?

Hepanova was founded by QISHENG LI, Frank Q. Li, T. Jake Liang.

How much funding has Hepanova raised?

Hepanova has disclosed $1.4M raised across 2 rounds.

Where is Hepanova headquartered?

Hepanova is headquartered in Gaithersburg, US.

Hepanova

Gaithersburg, US · California corporation

Hepanova is a clinical-stage biotech developing first-in-class oral small-molecule therapeutics for chronic liver diseases and inflammatory conditions, including MASH, liver fibrosis, and IBD. Its lead candidate, HPN-01, is an oral dual IKKα/IKKβ inhibitor that has completed a U.S. Phase 1 trial.

Biotech Deep Tech Healthtech

Founders & leadership

QISHENG LICo-founder

Frank Q. LiinFounder, President & CEO

T. Jake LiangCo-Founder

Mazen NoureddinChief Medical Officer

Belle X. WangChief Operating Officer

Ella LiinChief Business Officer

KE LINamed on SEC filing

Yuanzhang WangNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$1.4M disclosed across 2 rounds · 2019–2021

▶$450KraisedJan 2021 · 1 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

FRANK Q. LIExecutive Officer, Director
BELLE X WANGExecutive Officer, Director
YUANZHANG WANGDirector
KE LIDirector

Offering amount: $450K
Amount sold: $450K
First sale: Jan 2021
Incorporated: Corporation, California
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1MraisedOct 2019 · 1 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

QISHENG LIExecutive Officer, Director
KE LIDirector
Yuanzhang WangExecutive Officer, Director
Belle X WangExecutive Officer, Director

Offering amount: $1M
Amount sold: $1M
First sale: Oct 2019
Incorporated: Corporation, California
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Hepanova do?: Hepanova is a clinical-stage biotech developing first-in-class oral small-molecule therapeutics for chronic liver diseases and inflammatory conditions, including MASH, liver fibrosis, and IBD. Its lead candidate, HPN-01, is an oral dual IKKα/IKKβ inhibitor that has completed a U.S. Phase 1 trial.
Who founded Hepanova?: Hepanova was founded by QISHENG LI, Frank Q. Li, T. Jake Liang.
How much funding has Hepanova raised?: Hepanova has disclosed $1.4M raised across 2 rounds.
Where is Hepanova headquartered?: Hepanova is headquartered in Gaithersburg, US.